Galactosylated Macrolide Senolytics for Cancer Stem Cell Eradication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer therapies fail to effectively eradicate cancer stem cells (CSCs) and senescent cells, leading to tumor recurrence and metastasis, due to the unique genetic makeup of each patient's tumor and the resilience of CSCs to conventional treatments.

Innovation Solution

Development of macrolide compounds, such as Compound [I] (AZM-Gal), which selectively target and eradicate senescent cells and inhibit CSCs by modulating mitochondrial metabolism, thereby preventing tumor recurrence and metastasis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional cancer therapies (irradiation, alkylating agents, anti-metabolites) are used to eradicate cancer cells, then fast-growing cancer cells are eliminated, but cancer stem cells survive and lead to tumor recurrence

Engineering Contradiction:

Improvecancer cell eradication efficiencyVSAvoidtreatment completeness

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent modifies the chemical structure of macrolide compounds by conjugating galactose moieties to create galactosylated derivatives (e.g., AZM-Gal). This structural parameter change enables selective targeting of senescent cells and cancer stem cells through galactose-specific receptors, overcoming the limitation of conventional therapies that fail to eradicate these resilient cell populations

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The galactose moiety acts as an intermediary that mediates selective binding to galactose-specific receptors on senescent cells and cancer stem cells. This intermediary mechanism allows the macrolide compound to specifically target and eradicate these cell types while sparing normal dividing cells, thereby improving treatment completeness without sacrificing eradication efficiency

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If high doses of chemotherapeutic agents are used to ensure complete cancer cell eradication, then more cancer cells are killed, but resistance emerges and normal cells are damaged

Engineering Contradiction:

Improvecancer cell eradication completenessVSAvoidnormal cell damage and resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by directing the therapeutic action of macrolide compounds specifically to senescent cells and cancer stem cells through galactose-mediated targeting. This localized action concentrates the eradication effect on target cells while minimizing exposure and damage to normal dividing cells, thereby reducing harmful side effects and resistance development

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

Instead of targeting fast-growing cancer cells as conventional therapies do, the patent inverts the approach by targeting slow-growing or non-dividing senescent cells and cancer stem cells that express galactose-specific receptors. This inverted targeting strategy achieves complete eradication by eliminating the reservoir of resilient cells that conventional therapies miss

Inventive Principle:

Principle #13The other way round (Inversion)

3Productivity

If macrolide compounds are designed to have high antibiotic activity, then bacterial infections are treated effectively, but selectivity against senescent cells and cancer stem cells is reduced

Engineering Contradiction:

Improveantibiotic activityVSAvoidcell type selectivity

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent segments the functional properties of macrolide compounds by separating antibiotic activity from senolytic activity. The galactosylated macrolide compounds are designed to primarily exert senolytic effects through galactose-specific targeting, while their antibiotic activity is reduced or eliminated. This segmentation allows high selectivity for senescent cells and cancer stem cells without the confounding effect of broad-spectrum antibiotic activity

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds demonstrate high selectivity and potency against senescent cells and CSCs, reducing their propagation and inhibiting tumor growth, with minimal antibiotic activity, thus offering a novel approach to prevent cancer recurrence and metastasis.

Implementation Method 1

Development of macrolide compounds, such as AZM-Gal, that selectively target and eradicate senescent cells and inhibit CSCs by modulating mitochondrial metabolism

Methodology Applied

Scientific EffectMitochondrial metabolism modulation:

Data Source

PatentUS20260109725A1Macrolide senolytic compounds

Publication Date: 2026.04.23 LUNELLA BIOTECH INC

AI summary

Disclosed herein are macrolide compounds having senolytic activity. These compounds selectively target senescent cells, and may be used to reduce or eradicate senescent cells in a subject, and/or delay the onset of aging. These compounds also inhibit propagation of cancer stem cells, and may be used to treat cancer, and in particular inhibit the propagation of cancer stem cells responsible for metastasis and tumor recurrence. Formulae (I) & (II):